ASCO GU 2019 - Results from #140

Viewing 141-154 of 154 articles

ASCO GU 2019: Initial Results from Checkmate 650, a Phase II Study of Nivolumab Plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2019: Assessment of Circulating Tumor Cell Number as a Transitional Surrogate Endpoint for Survival in Phase II Trials for Metastatic Castrate-Resistant Prostate Cancer

ASCO GU 2019: Hypocalcemia in Patients with Castration-Resistant Prostate Cancer Treated with Denosumab: The REDUSE Trial

ASCO GU 2019: Practical Application of Genomic Assays in Clinical Decision Making

ASCO GU 2019: PSA Screening: Towards a Harm-Reduction Approach

ASCO GU 2019: Advanced Imaging and Biomarkers for Clinical Decision-Making: Where Are We Now?

ASCO GU 2019: The Role of MRI in Targeted Biopsy

ASCO GU 2019: Stereotactic Body Radiotherapy Compared to Conventionally Fractionated or Moderately Hypofractionated External Beam Radiotherapy for Localized Prostate Cancer

ASCO GU 2019: Quality-of-Life Assessment and Reporting in Prostate Cancer: A Systematic Review of Phase III Trials Published Between 2012 and 2016

Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer

Phase II Trial Shows Novel, Radiolabeled PSMA-Targeted Treatment Provides High Response Rates in Men with Metastatic Prostate Cancer

African-American Men with Advanced Prostate Cancer Live Longer Compared With White Men When Treated with Newer Hormone Therapies

Pembrolizumab Plus Axitinib Extended Overall Survival and Progress-Free Survival Versus Current Standard Treatment for Advanced Kidney Cancer

Blue Earth Diagnostics Announces Axumin® (Fluciclovine F 18) LOCATE Study Presentation at Upcoming ASCO 2019 Genitourinary Cancers Symposium on Impact on Clinical Management of Recurrent Prostate Cancer

1
2
3
4
5
6
7
8